Controlled-release approaches towards the chemotherapy of tuberculosis

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 5451-5463

  Saifullah, Bullo ^a   Hussein, Mohd Zobir B ^a   Al Ali, Samer Hasan Hussein ^a  

^a UNIVERSITY PUTRA MALAYSIA   (Malaysia)

Author keywords

Anti TB drug; Drug delivery system; Mycobacterium tuberculosis; Patient compliance; Targeted delivery; TB

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMINOSALICYLIC ACID; ASPARTIC ACID; BIOCERAMICS; CALCIUM PHOSPHATE; CAPREOMYCIN; CHITOSAN; CYCLOPEPTIDE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; GELATIN; GLUCAN; ISONIAZID; KANAMYCIN; MAGNESIUM TRISILICATE; MONTMORILLONITE; NANOCOMPOSITE; POLYVINYL ALCOHOL; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; THIOACETAZONE; THIOAMIDE; TRYPTOPHAN; TUBERCULOSTATIC AGENT; VEGETABLE PROTEIN;

ABDOMINAL PAIN; ACHILLES TENDON RUPTURE; ACIDIFICATION; ACUTE LIVER FAILURE; ADRENAL CORTEX INSUFFICIENCY; ANEMIA; ANOREXIA; ANTIBIOTIC SENSITIVITY; ANXIETY; APPETITE DISORDER; ARTHRALGIA; CELL SURVIVAL; COMBINATION CHEMOTHERAPY; CONTROLLED DRUG RELEASE; CONVULSION; CRANIAL NERVE INJURY; DEBRIDEMENT; DEPRESSION; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG ERUPTION; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG STABILITY; DRUG STRUCTURE; DRUG TARGETING; DRUG WITHDRAWAL; ENCAPSULATION; ERYTHRODERMA; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEVER; GASTRITIS; GASTROINTESTINAL SYMPTOM; GROWTH INHIBITION; GYNECOMASTIA; HEADACHE; HEARING IMPAIRMENT; HEMATOLOGIC DISEASE; HEPATITIS; HUMAN; HYDROGEL; IMPOTENCE; INJECTION SITE PAIN; INJECTION SITE RASH; KIDNEY DYSFUNCTION; LETHARGY; LIVER TOXICITY; LYSOSOME; MACROPHAGE; MENTAL DISEASE; MULTIDRUG RESISTANT TUBERCULOSIS; NAUSEA; NEPHROTOXICITY; NONHUMAN; ORAL PARESTHESIA; OSTEOMALACIA; OXIDATIVE STRESS; PAIN; PARTICLE SIZE; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PHAGOSOME; POROSITY; PRURITUS; PSEUDOMEMBRANOUS COLITIS; PSYCHOSIS; REVIEW; SIDE EFFECT; SIDEROBLASTIC ANEMIA; SKIN ALLERGY; SKIN MANIFESTATION; SKIN TINGLING; SOMNOLENCE; STEVENS JOHNSON SYNDROME; STOMACH DISEASE; STOMACH HEMORRHAGE; SUICIDE; SUSTAINED DRUG RELEASE; THIRST; THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; TREATMENT PLANNING; TUBERCULOSIS; TUBERCULOUS ARTHRITIS; VERTIGO; VESTIBULOCOCHLEAR NERVE INJURY; VOMITING;

ANTITUBERCULAR AGENTS; DELAYED-ACTION PREPARATIONS; DRUG DESIGN; HUMANS; NANOCAPSULES; TUBERCULOSIS;

MYCOBACTERIUM TUBERCULOSIS;

EID: 84870387407     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S34996     Document Type: Review

References (74)

1. World Health Orgnization (WHO) Report 2011. Global TB control. Available at http://www.who.int/tb/publications/global_report/en/.
2. Russell DG, Barry CE 3rd, Flynn JA. Tuberculosis: what we don't know can, and does, hurt us. Science. 2010;328(5980):852-856.
3. Chan ED, Iseman MD. Multidrug-resistant and extensively drug-resistant tuberculosis: a review. Curr Opin Infect Dis. 2008;21(6):587-595.
4. World Health Organization (WHO). XDR-TB: Extensively Drug-resistant Tuberculosis March 2007. Geneva: WHO; 2007. Available from: http://www.who.int/entity/tb/challenges/xdr/news_mar07.pdf. Accessed August 1, 2012.
5. Davies PD. Drug resistant tuberculosis. J R Soc Med. Jun 2001;94(6): 261-263.
6. Ryan KJ, Ray CG. Sherris Medical Microbiology: An Introduction to Infectious Diseases. 4th ed. New York, NY: McGraw-Hill; 2004.
7. Ferrari G, Langen H, Naito M, Pieters J. A coat protein on phagosomes involved in the intracellular survival of mycobacteria. Cell. 1999;97(4):435-447.
8. Meena LS, Rajani. Survival mechanisms of pathogenic Mycobacterium tuberculosis H37Rv. FEBS J. 2010;277(11):2416-2427.
9. Moulder JW. Comparative biology of intracellular parasitism. Microbiol Rev. 1985;49(3):298-337.
10. Gordon AH, Hart PA, Young MR. Ammonia inhibits phagosomes-lysosome fusion in macrophages. Nature. 1980;286(5768):79-81.
11. Crowle AJ, Dahl R, Ross E, May MH. Evidence that vesicles containing living, virulent Mycobacterium tuberculosis or Mycobacterium avium in cultured human macrophages are not acidic. Infect Immun. 1991;59(5):1823-1831.
12. Sturgill-Koszycki S, Schlesinger PH, Chakraborty P, etal. Lack of acidification in Mycobacterium phagosomes produced by exclusion of the vesicular proton-ATPase. Science. 1994;263(5147):678-681.
13. Yuan Y, Lee RE, Besra GS, Belisle JT, Barry CE 3rd. Identification of a gene involved in the biosynthesis of cyclopropanated mycolic acids in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A. 1995;92(14):6630-6634.
14. Falk R, Randolph TW, Meyer JD, Kelly RM, Manning MC. Controlled release of ionic compounds from poly (L-lactide) microspheres produced by precipitation with a compressed antisolvent. J Control Release. 1997;44(1):77-85.
15. Pandey R, Sharma A, Zahoor A, Sharma S, Khuller GK, Prasad B. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother. 2003;52(6):981-986.
16. WHO. Global Tuberculosis Control: Surveillance, Planning, Financing. WHO report WHO/HTM/TB/2005.349. Geneva: WHO; 2005. Available from: http://library.cphs.chula.ac.th/Ebooks/AnnualReport/WHOreport/WHOREPORT2005.pdf. Accessed August 1, 2012.
17. Fourth annual meeting of the Stop TB Working Group onDOTS-Plus for MDR-TB Paris, France October 27-28, 2003. http://whqlibdoc.who.int/hq/2004/WHO_HTM_TB_2004.341.pdf.
18. Zaleskis R. The side-effects of TB therapy. Breathe. 2005;2(1):5.
19. Prabakaran D, Singh P, Jaganathan K, Vyas SP. Osmotically regulated asymmetric capsular systems for simultaneous sustained delivery of anti-tubercular drugs. J Control Release. 2004;95(2):239-248.
20. Smith JP. Nanoparticle delivery of anti-tuberculosis chemotherapy as a potential mediator against drug-resistant tuberculosis. Yale J Biol Med. 2011;84(4):361-369.
21. Sosnik A, Carcaboso AM, Glisoni RJ, Moretton MA, Chiappetta DA. New old challenges in tuberculosis: potentially effective nanotechnologies in drug delivery. Adv Drug Deliv Rev. 2010;62(4-5):547-559.
22. Zhang L, Pornpattananangku D, Hu CM, Huang CM. Development of nanoparticles for antimicrobial drug delivery. Curr Med Chem. 2010;17(6):585-594.
23. Pandey R, Khuller G. Antitubercular inhaled therapy: opportunities, progress and challenges. J Antimicrob Chemother. 2005;55(4):430-435.
24. Fu J, Fiegel J, Krauland E, Hanes J. New polymeric carriers for controlled drug delivery following inhalation or injection. Biomaterials. 2002;23(22):4425-4433.
25. Batycky RP, Hanes J, Langer R, Edwards DA. A theoretical model of erosion and macromolecular drug release from biodegrading microspheres. J Pharm Sci. 1997;86(12):1464-1477.
26. Mader K, Gallez B, Liu KJ, Swartz HM. Non-invasive in vivo characterization of release processes in biodegradable polymers by low-frequency electron paramagnetic resonance spectroscopy. Biomaterials. 1996;17(4):457-461.
27. Shieh L, Tamada J, Chen I, Pang J, Domb A, Langer R. Erosion of a new family of biodegradable polyanhydrides. J Biomed Mater Res. 1994;28(12):1465-1475.
28. Visser J. Van der Waals and other cohesive forces affecting powder fluidization. Powder Technol. 1989;58(1):1-10.
29. Muttil P, Kaur J, Kumar K, Yadav AB, Sharma R, Misra A. Inhalable microparticles containing large payload of anti-tuberculosis drugs. Eur J Pharm Sci. 2007;32(2):140-150.
30. Donomae I. Capreomycin in the treatment of pulmonary tuberculosis. Ann N Y Acad Sci. 1966;135(2):1011-1038.
31. Garfield JW, Jones JM, Cohen NL, Daly JF, McClement JH. The auditory, vestibular and renal effects of capreomycin in humans. Ann N Y Acad Sci. 1966;135(2):1039-1046.
32. Brown J, Dooley D, Backer H. Drug-Resistant Tuberculosis: A Survival Guide for Clinicians. 1st ed. San Francisco, CA: Tuberculosis Reference Centre, California Department of Health Services, and Francis J Curry National Tuberculosis Centre; 2004.
33. O'Hara P, Hickey AJ. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization. Pharm Res. 2000;17(8):955-961.
34. Suarez S, O'Hara P, Kazantseva M, etal. Airways delivery of rifampicin microparticles for the treatment of tuberculosis. J Antimicrob Chemother. 2001;48(3):431-434.
35. Suarez S, O'Hara P, Kazantseva M, etal. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model. Pharm Res. 2001;18(9):1315-1319.
36. Edwards DA, Hanes J, Caponetti G, etal. Large porous particles for pulmonary drug delivery. Science. 1997;276(5320):1868-1871.
37. Garcia-Contreras L, Hickey AJ. Pharmacokinetics of aerosolized rifampicin in the guinea pig. In: Dalby RN, Byron PR, Peart J, Farr SJ, editors. Respiratory Drug Delivery VIII. Vol 2. Raleigh, NC: Davis Horwood International Publishing; 2002:699-702.
38. Garcia-Contreras L, Fiegel J, Telko MJ, etal. Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model. Antimicrob Agents Chemother. 2007;51(8):2830-2836.
39. Mizoe T, Ozeki T, Okada H. Application of a four-fluid nozzle spray drier to prepare inhalable rifampicin-containing mannitol microparticles. AAPS Pharm Sci Tech. 2008;9(3):755-761.
40. Sharma R, Saxena D, Dwivedi AK, Misra A. Inhalable microparticles containing drug combinations to targetalveolar macrophages for treatment of pulmonary tuberculosis. Pharm Res. 2001;18(10):1405-1410.
41. Kawashima Y, Serigano T, Hino T, Yamamoto H, Takeuchi H. Surface-modified antiasthmatic dry powder aerosols inhaled intratracheally reduce the pharmacologically effective dose. Pharm Res. 1998;15(11):1753-1759.
42. Malcolmson RJ, Embleton JK. Dry powder formulations for pulmonary delivery. Pharm Sci Technol Today. 1998;1:394-398.
43. O'Brien RJ. The treatment of tuberculosis. In: Reichman LB, Hershfield ES, editors. Tuberculosis: A Comprehensive International Approach: New York, NY: Marcel Dekker; 1993:1-20.
44. Soto E, Kim YS, Lee J, Kornfeld H, Ostroff G. Glucan particle encapsulated rifampicin for targeted delivery to macrophages. Polymers. 2010;2(4):681-689.
45. Aoudi M, Tesz GJ, Nicoloro SM et al. Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature. 2009; 458:1180-1184.
46. Soto ER, Ostroff GR. Characterization of multilayered nanoparticles encapsulated in yeast cell wall particles for DNA delivery. Bioconjug Chem. 2008;19(4):840-848.
47. Lawton JW. Zein: a history of processing and use. Cereal Chemistry. 2002;79(1):1-18.
48. Benita S, editor. Microencapsulation: Methods and Industrial Applications. New York, NY: Marcel Dekkar; 1996.
49. Kim BK, Hwang SJ, Park JB, Park HJ. Preparation and characterization of drug-loaded polymethacrylate microspheres by an emulsion solvent evaporation method. J Microencapsul. 2002;19(6):811-822.
50. Momany FA, Sessa DJ, Lawton JW, Selling GW, Hamaker SA, Willett JL. Structural characterization of alpha-zein. J Agric Food Chem. 2006;54(2):543-547.
51. Mehta SK, Kaur G, Verma A. Fabrication of plant protein microspheres for encapsulation, stabilization and in vitro release of multiple anti-tuberculosis drugs. Colloids Surf A Physicochem Eng Asp. 2011;375(1-3):219-230.
52. Ward AG. The Science and Technology of Gelatin. New York, NY: Academic Press; 1977.
53. Kaur A, Jain S, Tiwary AK. Mannan-coated gelatin nanoparticles for sustained and targeted delivery of didanosine: in vitro and in vivo evaluation. Acta Pharm. 2008;58(1):61-74.
54. Coester CJ, Langer K, van Briesen H, Kreuter J. Gelatin nanoparticles by two step desolvation-a new preparation method, surface modifications and cell uptake. J Microencapsul. 2000;17(2):187-193.
55. Verma AK, Sachin K, Saxena A, Bohidar HB. Release kinetics from bio-polymeric nanoparticles encapsulating protein synthesis inhibitor-cycloheximide, for possible therapeutic applications. Curr Pharm Biotechnol. 2005;6(2):121-130.
56. Saraogi GK, Gupta P, Gupta UD, Jain NK, Agrawal GP. Gelatin nanocarriers as potential vectors for effective management of tuberculosis. Int J Pharm. 2010;385(1-2):143-149.
57. Tabata Y, Ikada Y. Effect of the size and surface charge of polymer microspheres on their phagocytosis by macrophage. Biomaterials. 1988;9(4):356-362.
58. Hua S, Yang H, Wang W, Wang A. Controlled release of ofloxacin from chitosan-montmorillonite hydrogel. Appl Clay Sci. 2010;50(1): 112-117.
59. Mohanambe L, Vasudevan S. Inclusion of poly-aromatic hydrocarbon (PAH) molecules in a functionalized layered double hydroxide. J Chem Sci. 2006;118(1):105-115. Available from: http://www.ias.ac.in/chemsci/Pdf-Jan2006/105.pdf. Accessed August 1, 2012.
60. Akyuz S, Akyuz T. FT-IR and FT-Raman spectroscopic studies of adsorption of isoniazid by montmorillonite and saponite. Vib Spectrosc. 2008;48(2):229-232.
61. Hussein MZ, Al Ali SH, Zainal Z, Hakim MN. Development of antiproliferative nanohybrid compound with controlled release property using ellagic acid as the active agent. Int J Nanomedicine. 2011;6: 1373-1383.
62. Hussein Al Ali SH, Al-Qubaisi M, Hussein MZ, Zainal Z, Hakim MN. Preparation of hippurate-zinc layered hydroxide nanohybrid and its synergistic effect with tamoxifen on HepG2 cell lines. Int J Nanomedicine. 2011;6:3099-3111.
63. Panchagnula R, Agrawal S. Biopharmaceutic and pharmacokinetic aspects of variable bioavailability of rifampicin. Int J Pharm. 2004; 271(1-2):1-4.
64. Monkhouse DC, Lach JL. Use of adsorbents in enhancement of drug dissolution. II. J Pharm Sci. 1972;61(9):1435-1491.
65. Brindley GW. X-ray and electron diffraction data for sepiolite. Am Mineral. 1959;44:495-500.
66. Viçosa AL, Gomes AC, Soares BG, Paranhos CM. Effect of sepiolite on the physical properties and swelling behavior of rifampicin-loaded nanocomposite hydrogels. eXPRESS Polymer Letters. 2009;3:518-524.
67. Ruiz-Osuna C G-CR. Osteoarticular caseating tuberculosis of the hip: presenting as severe articular destruction. A case report. Acta Ortop Mex. 2008;22(4):254-258. Spanish.
68. Zhu M, Wang H, Liu J, etal. A mesoporous silica nanoparticulate/β-TCP/BG composite drug delivery system for osteoarticular tuberculosis therapy. Biomaterials. 2011;32(7):1986-1965.
69. Vallet Regí M, Ballas F, Arcos D. Mesoporous materials for drug delivery. Angew Chem Int Engl. 2007;46(40):7548-7558.
70. Mohanambe L, Vasudevan S. Orientational dynamics of anthracene in a cyclodextrin functionalized layered solid. J Phys Chem B. 2005;109(24):11865-11869.
71. Global Protein Products, Inc. Zein: a natural biopolymer from a renewable resource [web page on the Internet]. Fairfield, ME: Global Protein Products, Inc; 2011. Available from: http://www.globalprotein.com/zein.html. Accessed August 1, 2012.
72. S Benita, Microencapsulation: Methods and Industrial Applications. Marcel Dekkar, New York, 1996.
73. Ghanshyam V Joshi, Bhavesh D Kevadiya, Hasmukh A Patel, Hari C Bajaj, Raksh V Jasra. Montmorillonite as a drug delivery system: Intercalation and in vitro release of timolol maleate. International Journal of Pharmaceutics. 2009;374:53-57.
74. World Health Organization. Treatment of tuberculosis; Guidelines for national programme. WHO/CDS/TB; 2003.